Abstract
Background and Objective: The pace of innovation is accelerating and new preventative technologies for infectious diseases are emerging to address unmet medical needs. Most imminent is the use of long-acting monoclonal antibodies (mAb) to prevent Respiratory Syncytial Virus (RSV) lower...